ACINETWORK is a multidisciplinary network (7 academic groups and 1 industrial partner as Beneficiaries along with 8 Associated Partners) that aims to forge 10 young professionals within an integrated research training programme in academia and industrial environments on the design and development of novel glycoconjugate vaccine candidates as treatment against severe and life-threatening infections caused by the multidrug-resistant bacterium Acinetobacter baumannii, a major cause of nosocomial diseases.
The combination of the beneficiaries’ expertise in carbohydrate synthesis, conjugation techniques, nanotechnology, molecular glycobiology, cell biology, immunology and vaccinology, along with a wide experience in business and technological transfer, will create a multidisciplinary environment in which the Doctoral Candidates can nourish their skills and the most innovative ideas in the growing fields of glycoscience and vaccinology, and simultaneously acquire transferable know-how that will enable them to become the new leaders of academic or industrial research. In parallel, ACINETWORK will improve the European competitiveness and innovation capacity by bringing to market and policy stakeholders new glycoscience concepts in the development of novel therapeutic options to tackle unmet medical needs and major global healthcare challenges.